All In Biotech

Drug Trial Radar · NCT03287791

A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea

A Multicenter, Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled Study to Evaluate Safety and Clinical Equivalence of a Generic Azelaic Acid Foam, 15% and the Reference Listed Finacea® (Azelaic Acid) Foam,15% in Patients With Moderate Facial Rosacea

Last checked: Nov 19, 2026Latest source record: Jul 31, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 924 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

924

Actual

Start

Jul 19, 2016

Primary completion

Jun 22, 2017

Study completion Jun 22, 2017

Sponsor

Lead sponsor
Actavis Inc.Industry
Sponsor type
Industry
First posted
Sep 19, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this study were to compare the safety and efficacy profiles of a generic Azelaic Acid Foam, 15% to the reference listed Finacea® (azelaic acid) Foam, 15% and to demonstrate therapeutic equivalence and safety of the two active foams in the treatment of moderate facial rosacea, and to demonstrate superiority of the Reference and Test products over the Vehicle.

Conditions

  • Rosacea

Interventions

  • Generic Azelaic Acid FoamDrug

    Topical foam, generic formulation of the brand product.

  • Finacea® (Azelaic Acid) FoamDrug

    Topical foam, brand product.

  • Vehicle FoamDrug

    Topical foam, placebo. Has no active ingredient.

  • CleanserOther

    A mild cleanser provided to participants, so they can wash their face prior to applying the study drug.

  • SunscreenOther

    Sunscreen provided to participants, so they can apply it to their face when outdoors.

  • TowelOther

    A soft towel provided to participants, so they can pat their face dry after washing and prior to applying the study drug.

  • Moisturizing LotionOther

    Moisturizing lotion provided to participants, so they can apply it to their face, as needed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in the Inflammatory Lesions (Papules and Pustules) Counts at Week 12Time frame: Baseline, 12 weeks

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Investigative Site 2

    Encino, California

  • Investigative Site 10

    La Mesa, California

  • Investigative Site 19

    Brandon, Florida

  • Investigative Site 1

    Hialeah, Florida

  • Investigative Site 9

    Hialeah, Florida

  • Investigative Site 23

    Lauderdale Lakes, Florida

  • Investigative Site 11

    Miami, Florida

  • Investigative Site 15

    Miami, Florida

  • Investigative Site 20

    Miami, Florida

  • Investigative Site 12

    Miramar, Florida

  • Investigative Site 25

    Ocala, Florida

  • Investigative Site 22

    Pembroke Pines, Florida

  • Investigative Site 18

    Tampa, Florida

  • Investigative Site 16

    Savannah, Georgia

  • Investigative Site 14

    Plainfield, Indiana

  • Investigative Site 13

    Wichita, Kansas

  • Investigative Site 6

    New Orleans, Louisiana

  • Investigative Site 17

    Omaha, Nebraska

  • Investigative Site 8

    High Point, North Carolina

  • Investigative Site 3

    Cincinnati, Ohio

  • Investigative Site 21

    Philadelphia, Pennsylvania

  • Investigative Site 4

    Dallas, Texas

  • Investigative Site 26

    El Paso, Texas

  • Investigative Site 7

    New Braunfels, Texas

  • Investigative Site 5

    Norfolk, Virginia

  • Investigative Site 24

    Spokane, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.